MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Azalea Therapeutics
Organization & Developments: Azalea Therapeutics
Parents
Azalea Therapeutics
Children
*Biotech company revolutionizing genomic medicines by offering In Vivo cell-specific precision therapeutics for genetic diseases and cellular-based therapies
2025: Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient
2025: First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, durable gene expression for greater therapeutic impact
2025: Jennifer Doudna spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot
Jumps
Finance & Acquisition: Azalea Therapeutics
Key People: Azalea Therapeutics